Table 3.

QOL in LVB using validated tools.

Study	Year Published	Number of Patients	Stage	Lymphedema Site	Primary vs. Secondary	Surgical Procedure	Baseline QOL Measure Administered Pre-Operatively?	Average Follow-Up Time Regarding Subjective Assessment	QoL Measure	Percent of Patients with Subjective Improvement
Damstra et al.	2009	10	Campisi stage III (10)	UE	Secondary	LVB	Yes	6 mo	SF-36	50%
Cornelissen et al.	2017	20	ISL 1 (1), 2a (19)	UE	Secondary	LVB	Yes	12 mo	Lymph-ICF	Individual patient data not reported
Gentileschi et al.	2017	16	ISL 2a (7), 2b (9)	UE	Secondary	LVB	Yes	6 mo	LYMQOL	Individual patient data not reported
Winters et al.	2017	29	Campisi stages 1b–2a	UE	Secondary	LVB	Yes	12 mo	LYMQOL	Individual patient data not reported
Salgarello et al.	2018	74	Not mentioned	UE (44), LE (26)	Primary (5), Secondary (55)	LVB	Yes	8.5 mo	LYMQOL	Individual patient data not reported
Winters et al.	2019	12	Campisi stages 1–2a	UE	Secondary	LVB	Yes	6 mo	LYMQOL	Individual patient data not reported

ISL, international society of lymphology; UE, upper extremity; LE, lower extremity; LVB, lymphovenous bypass; mo, months; SF-36, short form 36 questionnaire; Lymph-ICF, lymphedema functioning, disability and health questionnaire; LYMQOL, lymph quality of life measure for limb lymphedema.